NCT05082779View on ClinicalTrials.gov

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

October 26, 2021

Primary Completion Date

September 16, 2022

Study Completion Date

October 12, 2022

Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
DRUG

CS0159

Tablets administered orally

Trial Locations (1)

32117

Labcorp Clinical Research Unit, Inc., Daytona Beach

Sponsors

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Cascade Pharmaceuticals, Inc

OTHER

NCT05082779 - Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 | Biotech Hunter | Biotech Hunter